NRO 1
Alternative Names: NRO-1; SI-01Latest Information Update: 28 Jul 2024
At a glance
- Originator Senju Pharmaceutical
- Developer Neuroptika
- Class Eye disorder therapies; Neuroprotectants; Small molecules
- Mechanism of Action Glial cell line-derived neurotrophic factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dry eyes
- No development reported Glaucoma; Keratitis; Leber's hereditary optic atrophy
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Keratitis in USA (Ophthalmic)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Glaucoma in USA (Ophthalmic)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Leber's-hereditary-optic-atrophy in USA (Ophthalmic)